The well-established clinical safety of BoNT/A in ophthalmic and neurologic indications (e.g., blepharospasm, migraine, strabismus) provides a foundation for repurposing it in retinal applications, potentially as an adjunct therapy to current anti-VEGF or corticosteroid treatments. The gene discussed is VEGFA; the disease is benign essential blepharospasm.